Browsing Artikler, rapporter og annet (samfunnsmedisin) by Author "Sørbye, Sveinung"
-
13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Up
Rad, Amir; Sørbye, Sveinung; Brenn, Tormod; Tiwari, Sweta; Løchen, Maja-Lisa; Skjeldestad, Finn Egil (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-02-25)Background: A specific, cost-effective triage test for minor cytological abnormalities is essential for cervical cancer screening among younger women to reduce overmanagement and unnecessary healthcare utilization. We compared the triage performance of one 13-type human papillomavirus (HPV) DNA test and one 5-type HPV mRNA test. Methods: We included 4115 women aged 25–33 years with a screening ... -
Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study
Westre, Bjørn; Giske, Anita; Guttormsen, Hilde; Sørbye, Sveinung; Skjeldestad, Finn Egil (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-11-05)Within 2021, Norway intends to complete implementation of HPV DNA-based primary screening for cervical cancer for women 34–69 years, while continue cytology-based screening for women 25–33 years. Over the recent years, the incidence of cervical cancer has increased by 30% among women younger than 40 years. In this subset of women, nearly 30% were diagnosed with a normal smear, as most recent smear, ... -
Recurrent disease after treatment for cervical intraepithelial neoplasia-The importance of a flawless definition of residual disease and length of follow-up
Bjørnerem, Mathilde Seeger; Sørbye, Sveinung; Skjeldestad, Finn Egil (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-09)Objective - To evaluate adherence to national guidelines for follow-up, and assess residual and recurrent disease after treatment for cervical intraepithelial neoplasia grade 2 or worse (CIN2+).<p> <p>Study design - In a case-series design women aged 25–69 years treated for primary CIN2+ in 2006–2011 (n = 752) were followed through August 9, 2019 for residual or recurrent disease, i.e., CIN2+ ...